EGFR and non-small cell lung carcinoma: The increased sensitivity to platinum-based therapies [57] and radiotherapy [56], enhanced response to target therapy (EGFR) [57], and improved outcomes with immune checkpoint inhibitors [6] in HPV-positive NSCLC represent significant advancements.